Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and durability of BI 3720931 gene therapy in cystic fibrosis (extension study)
2023-504909-37-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2024
- Modality
- Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 5
01
Overview
Phase 2, open-label trial of BI 3720931 in cystic fibrosis (CF) (2 cohorts), sponsored by Boehringer Ingelheim. Planned start Jun 2024; status: authorised.
02
Drugs
BI 3720931
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2023-504909-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504909-37-00.